Long-acting antiviral agents for HIV treatment

Current Opinion in HIV and AIDS

Volumn 10, Issue 4, 2015, Pages 246-252

  Margolis, David A ^a   Boffito, Marta ^b,c  

^a GLAXOSMITHKLINE   (United States)

^b Chelsea and Westminster Foundation Trust   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cabotegravir; HIV 1; Rilpivirine

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CABOTEGRAVIR; IBALIZUMAB; LONG ACTING DRUG; RILPIVIRINE; RITONAVIR; DELAYED RELEASE FORMULATION;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; DRUG FORMULATION; DRUG SAFETY; ERYTHEMA; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VIRUS LOAD; DELAYED RELEASE FORMULATION; HIV INFECTIONS;

ANTI-HIV AGENTS; DELAYED-ACTION PREPARATIONS; HIV INFECTIONS; HUMANS; RILPIVIRINE;

EID: 84943146144     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000169     Document Type: Review

References (17)

1. Coleman CI, Roberts MS, Sobieraj DM, et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012; 28:669-680.
2. Low-Beer S, Yip B, O'Shaughnessy MV, et al. Adherence totriple therapy and viral load response. J Acquir Immune Defic Syndr 2000; 23:360-361.
3. Nelson MR, Elion RA, Cohen CJ, et al. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies. HIV Clin Trials 2013; 14:81-91.
4. Baert L, van 't Klooster G, Dries W, et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm 2009; 72:502-508.
5. van 't Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010; 54: 2042-2050.
6. Verloes R, Deleu S, Niemeijer N, et al. Safety, tolerability and pharmacoki-netics of rilpivirine following administration of a long-acting formulation in healthy volunteers. HIV Med 2015; in press.
7. Jackson AG, Else LJ, Mesquita PM, et al. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for preexposure prophylaxis. Clin Pharmacol Ther 2014; 96:314-323.
8. Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 2013; 14:192-203.
9. Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 2013; 8:565-571.
10. Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr 2014; 67:481-486.
11. Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr 2014; 67:487-492.
12. Lou Y, Gould E, Chen S, et al. Meta-analysis of safety data from 8 clinical studies with GSK1265744, an HIV integrase inhibitor, dosed orally or as injection of long-acting parenteral nanosuspension (LAP) [Abstract 1752]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 10-13 September 2013; Denver, CO.
13. Margolis DA, Brinson CC, Eron JJ, et al. 744 and rilpivirine as two drug oral maintenance therapy: LAI116482 (LATTE) week 48 results [Abstract 91 LB]. 21st Conference on Retroviruses and Opportunistic Infections; 3-6 March 2014; Boston, MA.
14. Ford SL, Chiu J, Lovern M, et al. Population PK approach to predict cabotegravir (CAB, GSK1265744) long-acting injectable doses for phase 2b [Abstract H-645]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5-9 September 2014; Washington, DC, USA.
15. Bruno CJ, Jacobson JM. Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection. J Antimicrob Chemother 2010; 65:1839-1841.
16. Gautam N, Roy U, Balkundi S, et al. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob Agents Chemother 2013; 57:3110-3120.
17. Williams J, Sayles HR, Meza JL, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nano-medicine 2013; 8:1807-1813.